TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Bluejay Diagnostics ( (BJDX) ).
On July 23, 2025, Bluejay Diagnostics announced an amendment to its agreements with Toray Industries, extending the deadline to establish an alternative manufacturing site for Symphony cartridges to October 23, 2026. The amendment also confirms that Toray has fulfilled its know-how obligations and requires Bluejay to pay $71,212 for a final supply of chip components before the supply agreement expires on October 23, 2025.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Underperform.
Bluejay Diagnostics’ stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.
To see Spark’s full report on BJDX stock, click here.
More about Bluejay Diagnostics
Bluejay Diagnostics, Inc. operates in the medical diagnostics industry, focusing on developing and supplying diagnostic solutions, including the Symphony cartridges.
Average Trading Volume: 804,551
Technical Sentiment Signal: Sell
Current Market Cap: $2.33M
See more insights into BJDX stock on TipRanks’ Stock Analysis page.